- Home
- SUUN vs RLMD Comparison
SUUN vs RLMD Comparison
Compare SUUN & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUUN
- RLMD
- Stock Information
- Founded
- SUUN 2013
- RLMD 2004
- Country
- SUUN Canada
- RLMD United States
- Employees
- SUUN N/A
- RLMD N/A
- Industry
- SUUN
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- SUUN
- RLMD Health Care
- Exchange
- SUUN Nasdaq
- RLMD Nasdaq
- Market Cap
- SUUN 123.9M
- RLMD 110.6M
- IPO Year
- SUUN N/A
- RLMD N/A
- Fundamental
- Price
- SUUN $2.96
- RLMD $3.21
- Analyst Decision
- SUUN
- RLMD Hold
- Analyst Count
- SUUN 0
- RLMD 2
- Target Price
- SUUN N/A
- RLMD $7.50
- AVG Volume (30 Days)
- SUUN 31.2K
- RLMD 110.4K
- Earning Date
- SUUN 01-01-0001
- RLMD 11-07-2024
- Dividend Yield
- SUUN N/A
- RLMD N/A
- EPS Growth
- SUUN N/A
- RLMD N/A
- EPS
- SUUN N/A
- RLMD N/A
- Revenue
- SUUN $42,653,076.00
- RLMD N/A
- Revenue This Year
- SUUN N/A
- RLMD N/A
- Revenue Next Year
- SUUN N/A
- RLMD N/A
- P/E Ratio
- SUUN N/A
- RLMD N/A
- Revenue Growth
- SUUN 217.31
- RLMD N/A
- 52 Week Low
- SUUN $2.51
- RLMD $1.88
- 52 Week High
- SUUN $7.50
- RLMD $7.22
- Technical
- Relative Strength Index (RSI)
- SUUN 37.22
- RLMD 39.24
- Support Level
- SUUN $2.58
- RLMD $3.06
- Resistance Level
- SUUN $3.40
- RLMD $3.43
- Average True Range (ATR)
- SUUN 0.18
- RLMD 0.20
- MACD
- SUUN -0.04
- RLMD -0.04
- Stochastic Oscillator
- SUUN 36.67
- RLMD 16.30
About SUUN SolarBank Corporation Common Stock
SolarBank Corp is an independent renewable and clean energy project developer and asset operator based in Canada and the United States. It is engaged in the development and operation of solar photovoltaic power generation projects in the province of Ontario and the state of New York. The company operates in two principal geographical areas - Canada and United States with a substantial portion of its overall revenue being generated from United States.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.